IBI: BC384; Jelena Grahovac***, viši naučni saradnik, Institut za onkologiju i radiologiju Srbije u Beogradu; Polje: prirodno-matematičke i medicinske nauke; Period: 2018-2024;
eNauka profil: rp02463; ORCID: 0000-0003-1430-8682;
WOS indikatori: NR = 20; TC = 1288; HIndex = 11;
eNauka WOS indikatori: NR = 37; TC = 1288; HIndex = 11 ;
Lista A broj bodova: 90.36231 (569) 40.6%; Lista B broj bodova: 754.1624 (569) 4.2%; Lista C broj bodova: 0.000 (0) nan%; Lista A broj bodova kolaboracije: 0.00361 (373) 96.8%; Lista B broj bodova kolaboracije: 59.2032 (373) 8.6%;
Statistika svih rezultata
| Statistika | Ukupno | 2013-2024 | 2015-2024 | 2018-2024 | 2020-2024 |
|---|---|---|---|---|---|
| Broj rezultata | 20 | 15 | 11 | 10 | 8 |
| Broj citata | 1288 | 1020 | |||
| Broj M bodova | 103.00 | 103 | 97.00 | 79 | |
| Normirani broj citata | 977.61 | 754.16 | |||
| Normirani broj M bodova rezultata kategorije M21a++M21a+M21+M22+M23+M24 | 95.86 | 95.86 | 90.36 | 73.86 | |
| Normirani broj M bodova rezultata kategorije M11+M12+M13+M14+M41 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Normirani broj M bodova rezultata kategorije M11+M12+M13+M14+M41+M42 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Normirani broj M bodova rezultata kategorije M51 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Normirani broj M bodova rezultata kategorije M43+M44 | 0.00 | 0.00 | 0.00 | 0.00 |
Statistika rezultata nastalih u medunarodnim kolaboracijama
| Statistika | Ukupno | 2013-2024 | 2015-2024 | 2018-2024 | 2020-2024 |
|---|---|---|---|---|---|
| Broj rezultata sa 20 i više autora | 1 | 1 | 1 | 0 | 0 |
| Broj citata rezultata sa 20 i više autora | 344 | 296 | |||
| Broj M bodova rezultata M21a++M21a+M21+M22+M23 sa 20 i više autora | 0.00 | 0 | 0.00 | 0 | |
| Normirani broj citata rezultata sa 20 i više autora | 68.80 | 59.20 | |||
| Normirani broj M bodova rezultata M21a++M21a+M21+M22+M23 sa 20 i više autora | 0.00 | 0.00 |
Rezultati
| RB | IBI | Godina | Kat | Tip | Vrsta | Referenca | TC | TCP | BA | NBB | NTC | Naslov | Autori | 1. | BC384 | 2010 | E | JOURNAL OF PROTEOME RESEARCH Vol. 9 (7): # 3656 - 3663 (8), (DOI: 10.1021/pr100164x) JUL 2010WOS | 27 | 10 | 8 | 0 | 8.3333 | Proteomic Analysis of Laser Microdissected Melanoma Cells from Skin Organ Cultures | Hood B, Grahovac J, Flint M, Sun M, Charro N, Becker D, Wells A, Conrads T | 2. | BC384 | 2011 | E | FRONTIERS IN BIOSCIENCE-LANDMARK Vol. 16 (): # 815 - 837 (23), (DOI: 10.2741/3722) JAN 1 2011WOS | 69 | 41 | 5 | 0 | 41.0000 | Epithelial and mesenchymal phenotypic switchings modulate cell motility in metastasis | Wells A, Chao Y, Grahovac J, Wu Q, Lauffenburger D | 3. | BC384 | 2013 | E | TRENDS IN PHARMACOLOGICAL SCIENCES Vol. 34 (5): # 283 - 289 (7), (DOI: 10.1016/j.tips.2013.03.001) MAY 2013WOS | 166 | 145 | 5 | 0 | 145.0000 | Targeting tumor cell motility as a strategy against invasion and metastasis | Wells A, Grahovac J, Wheeler S, Ma B, Lauffenburger D | 4. | BC384 | 2013 | E | JOURNAL OF INVESTIGATIVE DERMATOLOGY Vol. 133 (1): # 210 - 220 (11), (DOI: 10.1038/jid.2012.263) JAN 2013WOS | 28 | 19 | 3 | 0 | 19.0000 | Melanoma Cell Invasiveness Is Promoted at Least in Part by the Epidermal Growth Factor-Like Repeats of Tenascin-C | Grahovac J, Becker D, Wells A | 5. | BC384 | 2014 | E | JOURNAL OF HEPATOLOGY Vol. 60 (6): # 1135 - 1142 (8), (DOI: 10.1016/j.jhep.2014.01.025) JUN 2014WOS | 38 | 37 | 14 | 0 | 15.4167 | Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats | Schwabl P, Payer B, Grahovac J, Klein S, Horvatits T, Mitterhauser M, Stift J, Boucher Y, Trebicka J, Trauner M, Angermayr B, Fuhrmann V, Reiberger T, Peck-Radosavljevic M | 6. | BC384 | 2014 | E | LABORATORY INVESTIGATION Vol. 94 (1): # 31 - 40 (10), (DOI: 10.1038/labinvest.2013.132) JAN 2014WOS | 44 | 38 | 2 | 0 | 38.0000 | Matrikine and matricellular regulators of EGF receptor signaling on cancer cell migration and invasion | Grahovac J, Wells A | 7. | BC384 | 2016 | E | CANCER DISCOVERY Vol. 6 (8): # 852 - 869 (18), (DOI: 10.1158/2159-8290.CD-15-1177) AUG 2016WOS | 344 | 296 | 27 | 0 | 59.2000 | Obesity-Induced Inflammation and Desmoplasia Promote Pancreatic Cancer Progression and Resistance to Chemotherapy | Incio J, Liu H, Suboj P, Chin S, Chen I, Pinter M, Ng M, Nia H, Grahovac J, Kao S, Babykutty S, Huang Y, Jung K, Rahbari N, Han X, Chauhan V, Martin J, Kahn J, Huang P, Desphande V, Michaelson J, Michelakos T, Ferrone C, Soares R, Boucher Y, Fukumura D, Jain R | 8. | BC384 | 2018 | M21a | E | Article | JOURNAL OF TISSUE ENGINEERING AND REGENERATIVE MEDICINE Vol. 12 (1): # E318 - E322 (5), (DOI: 10.1002/term.2481) JAN 2018WOS | 8 | 7 | 8 | 7.5000 | 5.8333 | Vascular beds maintain pancreatic tumour explants for ex vivo drug screening | Bazou D, Maimon N, Gruionu G, Grahovac J, Seano G, Liu H, Evans C, Munn L | 9. | BC384 | 2019 | M21a | E | Article | CANCER BIOLOGY & MEDICINE Vol. 16 (2): # 247 - + (18), (DOI: 10.20892/j.issn.2095-3941.2018.0375) MAY 2019WOS | 25 | 21 | 6 | 9.0000 | 21.0000 | Telmisartan induces melanoma cell apoptosis and synergizes with vemurafenib in vitro by altering cell bioenergetics | Grahovac J, Srdic-Rajic T, Santibañez J, Pavlovic M, Cavic M, Radulovic S | 10. | BC384 | 2020 | M21a+ | E | Review | DRUG RESISTANCE UPDATES Vol. 52 (): #100713 - (22), (DOI: 10.1016/j.drup.2020.100713) SEP 2020WOS | 72 | 63 | 10 | 20.0000 | 63.0000 | Repurposing old drugs to fight multidrug resistant cancers | Dinic J, Efferth T, García-Sosa A, Grahovac J, Padrón J, Pajeva I, Rizzolio F, Saponara S, Spengler G, Tsakovska I | 11. | BC384 | 2020 | M21a+ | E | Review | DRUG RESISTANCE UPDATES Vol. 53 (): #100715 - (22), (DOI: 10.1016/j.drup.2020.100715) DEC 2020WOS | 429 | 326 | 4 | 20.0000 | 326.0000 | Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance | Erin N, Grahovac J, Brozovic A, Efferth T | 12. | BC384 | 2020 | M23 | E | Article | RSC MEDICINAL CHEMISTRY Vol. 11 (3): # 378 - 386 (9), (DOI: 10.1039/c9md00597h) MAR 1 2020WOS | 20 | 14 | 9 | 2.1429 | 10.0000 | Synthesis and evaluation of anticancer activity of new 9-acridinyl amino acid derivatives | Rupar J, Dobricic V, Grahovac J, Radulovic S, Skok Z, Ilas J, Aleksic M, Brboric J, Cudina O | 13. | BC384 | 2021 | M24 | E | Book Chapter | MELANOMA: Methods and Protocols Vol. 2265 (): # 73 - 80 (8), (DOI: 10.1007/978-1-0716-1205-7_5) 2021WOS | 0 | 0 | 3 | 0 | 0.0000 | A Fluorescence-Based Assay for Measuring Glucose Uptake in Living Melanoma Cells | Grahovac J, Pavlovic M, Ostojic M | 14. | BC384 | 2023 | M21a | E | Article | JOURNAL OF MOLECULAR MEDICINE-JMM Vol. 101 (8): # 1001 - 1014 (14), (DOI: 10.1007/s00109-023-02339-y) AUG 2023WOS | 2 | 2 | 8 | 10.0000 | 1.6667 | Nischarin expression may have differing roles in male and female melanoma patients | Ostojic M, Jevric M, Mitrovic-Ajtic O, Zivic K, Tanic M, Cavic M, Srdic-Rajic T, Grahovac J | 15. | BC384 | 2023 | M21 | E | Article | CANCERS Vol. 15 (6): #1761 - (18), (DOI: 10.3390/cancers15061761) MAR 2023WOS | 4 | 1 | 9 | 5.7143 | 0.7143 | Prognostic Value of Combined Hematological/Biochemical Indexes and Tumor Clinicopathologic Features in Colorectal Cancer Patients-A Pilot Single Center Study | Cuk V, Karamarkovic A, Juloski J, Arbutina D, Radulovic R, Milic L, Kovacevic B, De L, Grahovac J | 16. | BC384 | 2024 | M21 | E | Article | PLOS ONE Vol. 19 (5): #e0299685 - (28), (DOI: 10.1371/journal.pone.0299685) MAY 23 2024WOS | 0 | 0 | 4 | 8.0000 | 0.0000 | Analysis of the nischarin expression across human tumor types reveals its context-dependent role and a potential as a target for drug repurposing in oncology | Ostojic M, Duric A, Zivic K, Grahovac J | 17. | BC384 | 2024 | M21 | E | Review | INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES Vol. 25 (23): #12669 - (19), (DOI: 10.3390/ijms252312669) DEC 2024WOS | 4 | 0 | 4 | 8.0000 | 0.0000 | Sex-Related Differences in Pancreatic Ductal Adenocarcinoma Progression and Response to Therapy | Grahovac J, Duric A, Tanic M, Krivokuca A | 18. | BC384 | 2025 | E | SEMINARS IN CANCER BIOLOGY Vol. 109 (): # 10 - 24 (15), (DOI: 10.1016/j.semcancer.2024.12.003) FEB 2025WOS | 8 | 0 | 7 | 0 | 0.0000 | Organoids, tissue slices and organotypic cultures: Advancing our understanding of pancreatic ductal adenocarcinoma through in vitro and ex vivo models | Aksoy S, Earl J, Grahovac J, Karakas D, Lencioni G, Sigirli S, Bijlsma M | 19. | BC384 | 2025 | E | SEMINARS IN CANCER BIOLOGY Vol. 114 (): # 242 - 255 (14), (DOI: 10.1016/j.semcancer.2025.07.004) SEP 2025WOS | 0 | 0 | 10 | 0 | 0.0000 | CRISPR/Cas9 genome engineering in PDAC: From preclinical studies to translation and clinical research | Lu Y, Stoof J, Tanoé Y, Walsh N, Bijlsma M, Lei H, Chen T, Grahovac J, Grützmann R, Pilarsky C | 20. | BC384 | 2025 | E | MOLECULES Vol. 31 (1): #125 - (24), (DOI: 10.3390/molecules31010125) DEC 29 2025WOS | 0 | 0 | 6 | 0 | 0.0000 | Newly Synthesized Telmisartan-Amino Acid Conjugates Exhibit Enhanced Cytotoxic Effects in Malignant Melanoma Cells | Vukadinovic D, Damjanovic A, Vukovic M, Cudina O, Grahovac J, Dobricic V |
|---|
27. 04. 2026.; 00:08:45; Trajanje procesiranja: 0.017 s
Legenda:
RB - redni broj rezultata
IBI - identifikacioni broj istraživača
Godina - godina u kojoj je rezultat publikovan (isključivo sa kompletnom paginacijom)
Kat - kategorija rezulata
Tip - tip rezultata (teorijski, simulacioni ili eksperimentalni)
Vrsta - vrsta rezultata
Referenca - referenca rezultata (bez autora i naslova rezultata) sa direktnim linkom na rezultat (ako ima DOI broj), sa linkom na zapis u eNauci ili WOS
TC - ukupan broj citata rezulata na dan 31. 1. 2026. godine
TCP - ukupan broj citata rezultata u periodu 2015-2024
BA - broj autora na rezultatu
NBB - normirani broj bodova rezultata
NTC - normirani broj citata rezultata u periodu 2015-2024
Naslov - naslov rezultata
Autori - spisak svih autora ili najviše prvih 30 autora
Primer:
Primer normiranja broja M poena i broja citata ostvarenih na jednom rezultatu: eksperimentalni rad sa 11 autora u časopisu kategorije M21a+ koji je publikovan 2020. godine, citiran je 65 puta, od čega 55 puta u periodu 2015-2024. godine.
Normirani broj M poena koje istraživač ostvaruje na rezultatu je 20/(1+0.2*(11-10))=16.6667 a normirani broj citata je 55/(1+0.2*(11-10))=45.8333.
Ukupan broj ostaverinih bodova utvrđuje se na naznačenom periodu za sabiranje normiranih M poena svakog istraživača i u periodu za određivanje ukupnog broja normiranih citata (2015-2024).